Cargando…

Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?

PURPOSE: To analyze the expression of somatostatin receptor (SSTR)2a and 5 by immunohistochemistry (IHC) in surgically resected somatotrophic pituitary adenomas and to associate expression rates with tumor size and clinical, biochemical, and histological parameters and response to somatostatin analo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rass, Lena, Rahvar, Amir-Hossein, Matschke, Jakob, Saeger, Wolfgang, Renné, Thomas, Aberle, Jens, Flitsch, Jörg, Rotermund, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818633/ https://www.ncbi.nlm.nih.gov/pubmed/34674191 http://dx.doi.org/10.1007/s42000-021-00327-w

Ejemplares similares

Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery—a retrospective, single-center study
por: Sumislawski, Piotr, et al.
Publicado: (2023)

The Diagnostic Impact of Epigenomics in Pituicyte-derived Tumors: Report of an Unusual Sellar Lesion with Extensive Hemorrhage and Necrotic Debris
por: Dottermusch, Matthias, et al.
Publicado: (2022)

4K 3-dimensional video microscope system (orbeye) for transsphenoidal pituitary surgery
por: Rotermund, Roman, et al.
Publicado: (2021)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Novel AIP mutation in exon 6 causing acromegaly in a German family
por: Detomas, M., et al.
Publicado: (2023)

The Potential of Self-Assessment and Associated Factors for Delayed Symptomatic Hyponatremia Following Transsphenoidal Surgery: A Single Center Experience
por: Roser, Pia, et al.
Publicado: (2022)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

What to report in sellar tumor MRI? A nationwide survey among German pituitary surgeons, radiation oncologists, and endocrinologists
por: Huckhagel, Torge, et al.
Publicado: (2023)

Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4
por: Börzsei, Rita, et al.
Publicado: (2022)

ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature
por: Sumislawski, Piotr, et al.
Publicado: (2022)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer
por: Dharan, Shalini Sree, et al.
Publicado: (2017)

Internal carotid artery false aneurysm as a fatal complication of transsphenoidal surgery
por: Sumislawski, Piotr, et al.
Publicado: (2021)

Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing’s disease
por: Huckhagel, Torge, et al.
Publicado: (2023)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)
por: Brunetti, Alessandro, et al.
Publicado: (2022)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas
por: Ricklefs, Franz L., et al.
Publicado: (2020)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Membrane-displayed somatostatin activates somatostatin receptor subtype-2 heterologously produced in Saccharomyces cerevisiae
por: Hara, Keisuke, et al.
Publicado: (2012)

Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review
por: Heidarpour, Maryam, et al.
Publicado: (2019)

Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs
por: Daniel, Charles P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ea3ihkva23r2gv6qemq97d1cfd